Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by a private equity firm in 2018
|
| gptkbp:ceo |
gptkb:Francesco_M._De_Luca
|
| gptkbp:clinical_trial |
Conducts clinical trials for new drugs
|
| gptkbp:employees |
Approximately 50
|
| gptkbp:focus |
Women's Health
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:headquarters |
gptkb:Boston,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Juniper Pharmaceuticals
|
| gptkbp:investment |
Various institutional investors
|
| gptkbp:market_cap |
Market capitalization in millions
|
| gptkbp:mission |
To improve the lives of patients through innovative therapies.
|
| gptkbp:partnership |
Collaboration with other biotech firms
|
| gptkbp:products |
JZP-110
JZP-150 JZP-258 |
| gptkbp:regulatory_compliance |
FDA approved products
|
| gptkbp:research_focus |
Drug development for rare diseases
|
| gptkbp:revenue |
Reported revenue in millions
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.juniperpharma.com
|
| gptkbp:bfsParent |
gptkb:Catalent
|
| gptkbp:bfsLayer |
5
|